Zobrazeno 1 - 10
of 2 979
pro vyhledávání: ''
Autor:
Jeff P. Sharman, Peter Trask, Yeung-Chul Mun, Anthony Masaquel, Habte A. Yimer, Alexey V. Danilov, John M. Burke, Sunil Babu, Jia Li, Michael Boxer
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 22:121-128
Introduction: Longitudinal changes in health-related quality of life (HRQoL) are important in patients with chronic lymphocytic leukemia (CLL). GIBB (NCT02320487) is an open-label, single-arm phase II study of obinutuzumab (GA101; G) in combination w
Autor:
Julie Means-Powell, Luis Del Valle, Vandana G. Abramson, Claudia Sorrentino, Melinda Sanders, Ingrid A. Mayer, Debra A. Tonetti, Roohi Ismail-Khan, Samarpan Majumder, Richard M Lush, Lucio Miele
Publikováno v:
Clin Breast Cancer
Preclinical studies have demonstrated a complex cross-talk between Notch and estrogen signaling in ERα-positive breast cancer. Gamma-secretase inhibitors (GSIs) are investigational agents that block the cleavage and activation of Notch receptors. In
Autor:
Stefanie D. Krens, Wim van Boxtel, Carla M.L. van Herpen, Sasja F. Mulder, Frank G A Jansman, Maike J. M. Uijen, Ingrid M.E. Desar, Nielka P. van Erp
Publikováno v:
International Journal of Cancer, 150, 308-316
International Journal of Cancer, 150, 2, pp. 308-316
International Journal of Cancer, 150(2), 308-316. Wiley
International Journal of Cancer, 150, 2, pp. 308-316
International Journal of Cancer, 150(2), 308-316. Wiley
Contains fulltext : 249093.pdf (Publisher’s version ) (Open Access) Cabozantinib is registered in fixed 60 mg dose. However, 46% to 62% of patients in the registration studies needed a dose reduction due to toxicity. Improved clinical efficacy has
Publikováno v:
Nitric Oxide. 118:17-25
AIMS Patients with type 2 diabetes mellitus (T2DM) have reduced vasodilatory responses during exercise partially attributable to low nitric oxide (NO) levels. Low NO contributes to greater α-adrenergic mediated vasoconstriction in contracting skelet
Autor:
Marco Pavesi, Moisés Mira Flores, Aurea Duran, Josep Gumà, Alessandra Pranzo, Alexis Serikoff, Bernard Rappe, Angus Robinson, Serena Hilman, Benoit Baron, Louis-Marie Dourthe, D. Mott, Steven Joniau, M. Herdman, Stéphane Mallick, Roberto Bordonaro, Maria De Santis, Ugo De Giorgi, Heather Payne
Publikováno v:
International Journal of Cancer. 150:837-846
In randomized clinical trials, the androgen-receptor inhibitor enzalutamide has demonstrated efficacy and safety in metastatic castration-resistant prostate cancer (mCRPC). This study captured efficacy, safety and patient-reported outcomes (PROs) of
Publikováno v:
Cancer Medicine
Cancer Medicine, Vol 10, Iss 24, Pp 8789-8798 (2021)
Cancer Medicine, Vol 10, Iss 24, Pp 8789-8798 (2021)
Preclinical observations that killing of chronic lymphocytic leukemia (CLL) cells was dexamethasone (DEX) were enhanced by concomitant inhibition of Bruton’s tyrosine kinase and janus kinases (JAKs) motivated a phase II trial to determine if clinic
Autor:
Guilherme Cantuaria, Paul DiSilvestro, Kirsty Rhodes, Lucy Gilbert, Johanna Mäenpää, Christian Marth, Maria Jesus Rubio Pérez, Koji Matsumoto, Claire Garnier-Tixidre, Ayumi Shikama, Isabelle Ray-Coquard, Philipp Harter, Daniel M. Anderson, Magdalena Sikorska, Francesco Raspagliesi, Ignace Vergote, Mario Ouwens, Robert Hettle, Domenica Lorusso, Kathleen N. Moore, Andres Poveda, Nicoletta Colombo, Ronnie Shapira-Frommer
Publikováno v:
European Journal of Cancer. 157:415-423
BACKGROUND: In the absence of randomised head-to-head trials, we conducted a population-adjusted indirect treatment comparison (PA-ITC) of phase III trial data to evaluate the relative efficacy and safety of maintenance olaparib and bevacizumab alone
Publikováno v:
BMC Cancer, Vol 21, Iss 1, Pp 1-8 (2021)
BMC Cancer
BMC cancer, Vol. 21, no. 1, p. 1204 (2021)
BMC cancer, Vol. 21, no. 1, p. 1204 [1-8] (2021)
BMC Cancer
BMC cancer, Vol. 21, no. 1, p. 1204 (2021)
BMC cancer, Vol. 21, no. 1, p. 1204 [1-8] (2021)
Background Trastuzumab emtansine (T-DM1) is indicated as second-line treatment for human epidermal growth factor receptor 2 (HER2)-positive metastatic or unresectable locally advanced breast cancer, after progression on trastuzumab and a taxane-based
Autor:
Marie C Semira, Francis Parnis, Angelyn Anton, Peter Gibbs, Arun Azad, Javier Torres, Lavinia Spain, Ashray Gunjur, Andrew Weickhardt, Phillip Parente, Jeffrey C. Goh, Edmond M. Kwan, Shirley Wong, Ben Tran, Carmel Pezaro, J. Shapiro
Publikováno v:
European Journal of Cancer. 157:485-492
INTRODUCTION: Bone metastases occur frequently in castration-resistant prostate cancer (CRPC) and may lead to skeletal-related events (SREs), including symptomatic skeletal events (SSEs). Bone-modifying agents (BMAs) delay SREs and SSEs. However, the
Autor:
Shi Ming Tu, Sumit K. Subudhi, Ana Aparicio, Ioannis Alafis, Brian F. Chapin, Xuemei Wang, Myrto Boukovala, Paul G. Corn, Nicholas Spetsieris, John C. Araujo, Justin A. Weldon, Eleni Efstathiou, Jennifer Wang, Lisa Pruitt, Christopher J. Logothetis, Amado J. Zurita, John Papadopoulos, John J. Davis
Publikováno v:
European Journal of Cancer. 157:259-267
Background Intermittent androgen deprivation therapy (ADT) in biochemically recurrent castration-naive prostate cancer is non-inferior to continuous therapy. We hypothesised that finite-duration abiraterone acetate plus prednisone (Abi +P) added to A